AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $105.69
- 52-wk high
- $134.38
- High
- $106.86
- 52-wk low
- $81.39
- Low
- $104.78
- Prev close
- $105.52
- Mkt cap
- $180.03B
- P/E
- 34.0x
- Volume
- 6.47M
- Fwd P/E
- 17.4x
- Beta
- 0.59
- Div yield
- 2.36%
- P/S
- 3.8x
- P/B
- 3.6x
- Profit margin
- +11.7%
- Op margin
- +14.7%
- ROE
- +10.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net buying.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 2.3% above what analysts expected.
Earnings per share
$1.28 expected
Revenue
No comparable estimate
Reports Oct 14, 2026, in 31 days
EPS expected
$1.41 to $1.44
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.14B | $11.37B | $11.46B | $11.16B |
| Cost of what it sold | $4.85B | $5.03B | $4.92B | $4.88B |
| Gross profit | $6.29B | $6.34B | $6.54B | $6.28B |
| What it spent | ||||
| Research and development | $732.0M | $785.0M | $735.0M | $756.0M |
| Sales and admin | $3.09B | $3.05B | $3.13B | $3.74B |
| Other operating costs | $414.0M | $472.0M | $422.0M | -$55.0M |
| Total operating expenses | $4.24B | $4.31B | $4.29B | $4.44B |
| What was left | ||||
| Operating profit | $2.05B | $2.06B | $2.25B | $1.84B |
| Interest on debt | $121.0M | $44.0M | $120.0M | $174.0M |
| Profit before tax | $2.15B | $2.18B | $2.36B | $1.45B |
| Tax | $371.0M | $536.0M | $582.0M | $372.0M |
| Net profit | $1.78B | $1.64B | $1.78B | $1.08B |
| EBITDA | $3.05B | $3.09B | $2.82B | $2.25B |
Technicals
Price structure
This stock's price action is mixed, and looks oversold after a sharp drop.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Stryker stock falls on slower peripheral vascular, hip sales
NeutralSep 10Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit
BearishSep 10Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
Leans bullishSep 9Abbott garners FDA nod for its TactiFlex catheter to treat AFib
BullishSep 9Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
Leans bearishSep 8Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
NeutralSep 8Abbott Laboratories stock holds valuation premium amid steady earnings
BullishSep 7Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets
BullishSep 7
Macro
30 macro signals shaping ABT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results